Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 1730

MacroGenics pauses development of ADC; Cellectis deprioritizes CAR-T

$
0
0
Plus, news about Tango Therapeutics, Endo, Neurogene and Century Therapeutics: MacroGenics stopped dosing patients in ADC trial: After three patient deaths in a Phase 2 prostate cancer drug trial for vobra duo ...

Viewing all articles
Browse latest Browse all 1730

Trending Articles